Login to Your Account

Financings Roundup

Transcept Seeks $40.5M to Attack Trio of Business Goals

By Marie Powers
Staff Writer

Friday, April 27, 2012
After moving insomnia drug Intermezzo (zolpidem tartrate) through the approval process, Transcept Pharmaceuticals Inc. is seeking to raise $40.5 million in an underwritten public offering of 4.5 million shares of common stock as the company turns its attention to TO-2061, a low-dose formulation of ondansetron as adjunctive treatment for obsessive compulsive disorder (OCD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription